SynthesisBMC infectious diseases2024
"High specificity of PCR in diagnosing mucocutaneous leshminiasis: a systematic review and meta analysis".
Synthesis in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of a commercial real-time PCR assay targeting Leishmania spp. with microscopically positive skin biopsies obtained from Nigerian patients.European journal of microbiology & immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucocutaneous leishmaniasis (MCL) is a severe form of leishmaniasis causing chronic and destructive lesions. Accurate diagnosis is crucial for effective treatment. Traditional methods, such as the Montenegro skin test is delayed hypersensitivity test. Polymerase chain reaction (PCR) has emerged as a superior diagnostic tool for detecting Leishmania DNA, offering higher sensitivity and specificity. METHODOLOGY: This meta-analysis adhered to PRISMA guidelines and included studies focusing exclusively on the diagnostic accuracy of PCR for MCL. A comprehensive literature search was conducted across multiple databases. Inclusion criteria mandated studies with relevant diagnostic accuracy metrics, while those mixing other forms of leishmaniasis or lacking a control group were excluded. Quality was assessed using the STARD checklist, and ensuring a low risk of bias assessed through QUADAS-2 tool.
resultsEight studies were included, showing PCR sensitivity ranging from 50% to 97.1% and consistently high specificity, often reaching 100%. The studies demonstrated a low risk of bias and applicability concerns, supporting the robustness of the findings. Heterogeneity was substantial, necessitating a random-effects model for pooled estimates. INTERPRETATIONS: This analysis confirms PCR's high specificity for MCL diagnosis, despite variable sensitivity. Compared to previous meta-analyses, this study's focus on MCL exclusively provides a more targeted evaluation. Future research should aim to standardize PCR protocols and explore non-invasive sampling techniques to enhance diagnostic accuracy and patient comfort, ultimately improving clinical outcomes for MCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.